Biogen Inc (BIIB)

Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell

$128.52

Buy

$130.51

arrow-down$-2.96 (-2.23%)

Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
Prices updated at 30 May 2025, 22:38 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-down-0.32%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.

Income statement

Year
chevron-l-regular
chevron-r-regular
20172018201920202021202220232024
12,274m13,453m14,378m13,445m10,982m10,173m9,836m9,676m
10,644m11,637m12,423m11,639m8,872m7,895m7,302m7,366m
5,529m6,001m7,036m4,446m2,808m2,902m1,831m2,219m
45.0544.6148.9333.0725.5728.5218.6222.93
2,539m4,431m5,889m4,001m1,556m3,047m1,161m1,632m
6,461m6,848m7,803m5,735m2,880m4,357m2,039m2,830m
Sales, General and administrative1,934m2,106m2,375m2,505m2,674m2,404m2,550m2,404m
Interest expenses251m201m187m223m254m247m247m250m
Provision for income taxes2,459m1,426m1,158m992m53m633m135m274m
Operating expenses5,115m5,636m5,387m7,193m6,064m4,993m5,471m5,147m
Income before taxes5,129m5,900m7,126m5,048m1,745m3,592m1,297m1,906m
Net income available to common shareholders2,539m4,431m5,889m4,001m1,556m3,047m1,161m1,632m
11.9421.6331.4724.8610.4420.968.0211.21
Net interest income-172m-88m-67m-180m-243m-157m30m-183m
Advertising and promotion--------
Net investment income, net--------
Realised capital gains (losses), net--------
Total benefits, claims and expenses--------
Earnings per share (diluted)11.9221.5831.4224.810.420.877.9711.18
Free cash flow per share12.600323.309633.089534.912713.931214.83237.053412.1144
Book value/share60.806169.810380.343970.593870.951788.718899.9572112.2631
Debt equity ratio0.4705540.4552670.3651070.7315870.606120.4936590.4857090.292038

Balance sheet

Year
chevron-l-regular
chevron-r-regular
20172018201920202021202220232024
Current assets7,873m7,641m8,382m6,887m7,857m9,791m6,859m7,457m
Current liabilities3,368m3,295m4,864m3,742m4,298m3,273m3,434m5,529m
Total capital18,548m18,976m17,802m18,127m17,170m19,679m21,588m21,263m
Total debt5,938m5,937m6,368m7,828m7,604m6,614m7,338m6,630m
Total equity12,613m13,040m13,343m10,700m10,896m13,398m14,799m16,716m
Total non current liabilities--------
Loans5,935m5,937m4,459m7,426m6,274m6,281m6,788m4,547m
Total assets23,653m25,289m27,234m24,619m23,877m24,554m26,845m28,049m
Total liabilities--------
Cash and cash equivalents1,574m1,225m2,914m1,331m2,261m3,419m1,050m2,375m
Common stock212m197m174m152m147m144m145m146m

Cash flow

Year
chevron-l-regular
chevron-r-regular
20172018201920202021202220232024
Cash at beginning of period2,327m1,574m1,225m2,914m1,331m2,261m3,419m1,050m
Cash dividends paid--------
2,588m5,302m6,409m3,678m3,345m1,141m1,236m2,516m
Investments (gains) losses-2,963m-2,046m471m-609m-564m1,577m-4,101m-799m
1,574m1,225m2,914m1,331m2,261m3,419m1,050m2,375m
Net income--------
4,551m6,188m7,079m4,230m3,640m1,384m1,547m2,876m
-1,963m-886m-669m-552m-295m-243m-311m-360m
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.